Texas Retina’s Ashkan M. Abbey, MD, recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant for the management of cystoid macular edema (CME) in a 6-year-old boy with a history of Coats’ disease.
A rare congenital, nonhereditary eye disorder, Coats’ disease is characterized by abnormal development of blood vessels behind the retina and can cause partial or full blindness. Cystoid macular edema is a disorder affecting the macula, which is the central part of the retina, resulting in cyst-like areas of fluid that cause retinal swelling (edema).
In this case, the patient had previously been treated with a combination of peripheral retinal laser, anti-vascular endothelial grown factor injections, and short-acting injectable steroids to control his disease process. The short-acting steroids had worked well but required general anesthesia for each procedure. To help decrease the treatment burden, Dr. Abbey, in consultation with the patient’s family, administered the injectable fluocinolone acetonide implant 0.18 mg (YUTIQ), a longer-acting steroid commercially available to treat chronic posterior noninfectious uveitis. At 30 months follow-up, the patient’s CME was controlled.
Click here to access the full article.
Dr. Abbey serves as Texas Retina’s Director of Clinical Research for Dallas and cares for patients in our Dallas Main and Rockwall offices. You can learn more about him here.